Polycystic Kidney Disease Clinical Trials
Here is the most popular medical study for polycystic kidney disease
PKD Clinical Trials
View 9 PKD medical studies.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor
Empagliflozin for Polycystic Kidney Disease
This trial will test if a drug called empagliflozin is safe and tolerable for people with a kidney disease called ADPKD. The trial will last 12 months and will involve 50 people.
Frequently Asked Questions
Introduction to polycystic kidney disease
What are the top hospitals conducting polycystic kidney disease research?
In the realm of revolutionary clinical trials for polycystic kidney disease (PKD), several top-notch hospitals are making significant strides. At Mayo Clinic in Rochester, Minnesota, researchers are currently engaged in two active PKD trials, building upon their brief but promising history of involvement. Having recorded their first trial dedicated to this condition in 2022, they have already established themselves as a crucial player in advancing our understanding and treatment options for PKD. In Boston's Tufts Medical Center, similar efforts are underway with two ongoing PKD trials and an impressive track record of nine completed studies since embarking on their initial investigation back in 2010.
Meanwhile, Children's National Medical Center located in Washington, Minnesota, researchers are currently engaged in two active PKD trials, building upon their brief but promising history of involvement. Having recorded their first trial dedicated to this condition in 2022, they have already established themselves as a crucial player in advancing our understanding and treatment options for PKD. In Boston's Tufts Medical Center, similar efforts are underway with two ongoing PKD trials and an impressive track record of nine completed studies since embarking on their initial investigation back in 2010.
Meanwhile, Children's National Medical Center located in Washington D.C., has also emerged as a key institution focused on tackling PKD through its commitment to groundbreaking research. With two active clinical trials at present and having initiated their very first study on the subject alongside Mayo Clinic and Northwestern University Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago - Neonatology just recently in 2022.
Noteworthy contributions can also be seen at Cleveland Clinic where they hold two current polycystic kidney disease experiments accompanied by six past investigations that've been instrumental towards enhancing knowledge about this ailment since commencing ventures from2012 onward.
Finally, Northwestern University Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital focuses not only on pediatric care but is actively involved in advancing knowledge about PKD as well through its institute specializing specifically neonatology; together with aforementioned institutions starting off simultaneous comprehensive examination into it by initiating notable new investigational protocols being taken up from this year onwards.The collective efforts displayed across these prestigious hospitals truly showcase dedication while accentuating potential breakthroughs that may offer hope to individuals affected by polycystic kidney disease globally
Which are the best cities for polycystic kidney disease clinical trials?
The best cities for polycystic kidney disease clinical trials include Chicago, Illinois, Rochester, Minnesota, Los Angeles, California, Baltimore, Maryland, and Boston Massachusetts, California, Baltimore, Maryland, and Boston Massachusetts. These cities have a significant number of active trials focused on studying potential treatments such as RGLS8429 and Tolvaptan (OPC-41061), among others. By participating in these clinical trials in these locations, individuals with polycystic kidney disease have the opportunity to contribute to advancements in research and potentially access innovative treatment options that can improve their quality of life.
Which are the top treatments for polycystic kidney disease being explored in clinical trials?
In the realm of polycystic kidney disease, clinical trials are illuminating potential breakthroughs in treatment. RGLS8429 stands at the forefront, currently being explored in one active trial for this condition. Joining its ranks is empagliflozin, which has also caught researchers' attention with one ongoing trial dedicated to polycystic kidney disease. Additionally, tolvaptan (OPC-41061) and tolvaptan tablets have entered the spotlight as both treatments are under investigation in respective trials for this debilitating disease. As these trials progress, hope grows that innovative solutions may soon emerge for individuals living with polycystic kidney disease.
What are the most recent clinical trials for polycystic kidney disease?
Exciting progress is being made in the realm of polycystic kidney disease (PKD) through recent clinical trials. One notable trial involves the use of hydrochlorothiazide, a medication that shows promise in managing PKD symptoms. Additionally, empagliflozin has been investigated for its potential benefits in treating this condition. Another study explores RGLS8429, aiming to provide valuable insights into novel therapeutic approaches for PKD patients. Tolvaptan tablets and tolvaptan (OPC-41061) have also undergone rigorous testing and evaluation as potential treatment options for individuals with polycystic kidney disease. These ongoing trials offer hope for improved management and outcomes for those affected by this chronic condition
What polycystic kidney disease clinical trials were recently completed?
In October 2017, Kadmon Corporation, LLC concluded a significant clinical trial investigating the potential of Tesevatinib in treating polycystic kidney disease. This trial represents an important step forward in understanding and addressing this challenging condition.